Inequalities in medicine use in Central Eastern Europe: an empirical investigation of socioeconomic determinants in eight countries

Abstract

BackgroundEquitable access to essential medicines is a major challenge for policy-makers world-wide, including Central and Eastern European countries. Member States of the European Union situated in Central and Eastern Europe have publicly funded pharmaceutical reimbursement systems that should promote accessibility and affordability of, at least essential medicines. However, there is no knowledge whether socioeconomic inequalities exist in these countries. Against this backdrop, this study analyses whether socioeconomic determinants influence the use of prescribed and non-prescribed medicines in eight Central and Eastern European countries (Bulgaria, Czech Republic, Hungary, Latvia, Poland, Romania, Slovenia, Slovakia). Further, the study discusses observed (in)equalities in medicine use in the context of the pharmaceutical policy framework and the implementation in these countries.MethodsThe study is based on cross-sectional data from the first wave of the European Health Interview Survey (2007–2009). Multivariate logistic regression analyses were carried out to determine the association between socioeconomic status (measured by employment status, education, income; controlled for age, gender, health status) and medicine use (prescribed and non-prescribed medicines). This was supplemented by a pharmaceutical policy analysis based on indicators in four policy dimensions (sustainable funding, affordability, availability and accessibility, and rational selection and use of medicines).ResultsOverall, the analysis showed a gradient favouring individuals from higher socioeconomic groups in the consumption of non-prescribed medicines in the eight surveyed countries, and for prescribed medicines in three countries (Latvia, Poland, Romania). The pharmaceutical systems in the eight countries were, to varying degrees, characterized by a lack of (public) funding, thus resulting in high and growing shares of private financing (including co-payments for prescribed medicines), inefficiencies in the selection of medicines into reimbursement and limitations in medicines availability.ConclusionPharmaceutical policies aiming at reducing inequalities in medicine use require not only a consideration of the role of co-payments and other private expenditure but also adequate investment in medicines and transparent and clear processes regarding the inclusion of medicines into reimbursement.Electronic supplementary materialThe online version of this article (doi:10.1186/s12939-015-0261-0) contains supplementary material, which is available to authorized users.

Affordable and equitable access to subsidised outpatient medicines? Analysis of co-payments under the Additional Drug Package in Kyrgyzstan

“…Similar conclusions on inequity were drawn in a recent Organisation for Economic Co-operation and Development (OECD) review: it concluded that Kyrgyz co-payment regulation in health care (not necessarily focused on medicines) was not designed to promote equity, and targeted poor and rural populations ineffectively [8]. This adds to the policy recommendation expressed in several reports that co-payments should be designed in a way that exempts specific population groups [34,44,60,68,71,72].…”

“…In addition, further policies could also contribute to improve equity in medicine use and reduce OOP payments for medicines. These include ensuring sufficient public funding of the health care system; inclusion of medicines that serve patients' priority health needs, with careful selection based on their therapeutic benefits and costeffectiveness; enhancing the uptake of generics and lowerpriced medicines; implementing a strategic design of the pharmaceutical reimbursement policy framework and formulating a co-payment regulation containing reductions and exemptions for populations that require stronger financial protection since patient payments are likely to lead to adverse health outcomes among people on low incomes, older people and patients with chronic conditions, partly through reduced adherence to essential medicines [60,71,72,[95][96][97][98][99]. A combination of policies is favourable [83].…”

Consumption and Lack of Access to Medicines and Associated Factors in the Brazilian Amazon: A Cross-Sectional Study, 2019

“…The lower use of medicines among the poor may have worsened due to the recent changes in the Farmácia Popular program – a governmental initiative created in 2004 with the aim of increasing access to medicines with lower prices –, which could potentially result in higher expenditures with treatments for several Brazilian families ( Trindade, 2018 ). In the present study, as consumption was not restricted only to essential medicines provided by SUS, it is possible that individuals from higher social classes used more medicines due to their higher purchasing power, as indicated by a previous analysis ( Vogler et al., 2015 ).…”

The impact of scientific evidence and price level of hypertension drug therapies on their market performance – A Europe based analysis

“…0 ( Generic price depends on the price of the innovator - Author's edit, Source: Barbu, 2012;Dylst et al, 2012;Kaplan et al, 2012;2011a,2011bPanteli et al, 2016;Thomson-Mossialos 2010;Vogler, 2012;Vogler et al, 2015) XLVIII. ÉVF.…”